Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Digirad Corporation (Nasdaq: DRAD) today announced that it has sent ... ), a healthcare commercialization services company, responding to PDI,s ... Digirad calls upon PDI to immediately ... operate in the ordinary course of business and to ... on acquisitions or other extraordinary transactions. Digirad believes that ...
(Date:10/31/2014)... Oct. 31, 2014  Grammy Award-winner Bruce Hornsby ... audience of philanthropists, athletes, actors, and musicians during the ... November 19 at the Mandarin Oriental Hotel in ... event will honor six individuals who embody the values ... will bestow its highest honor, the Spirit of an ...
(Date:10/31/2014)... -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased ... combination with gemcitabine, will be reimbursed via the Pharmaceutical ... from 1 November. In ... most common cause of cancer mortality. Pancreatic cancer ... lowest 5-year survival of all common cancers at 5.2%. ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 510th Anniversary Orthopaedic Foundation Gala Set For Success 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... Miami Beach, Florida (PRWEB) October 31, 2014 ... Hydroponics” or, the “Company”) today announced it has signed ... three Canada-based companies in the urban cultivation sector - ... Ltd. (BC Northern Lights”), and W3 Metal Inc. (“W3 ... Lights, the “Target Companies”). Pursuant to the LOI ...
(Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
(Date:10/31/2014)... 31, 2014 Phoenix dentist , Dr. ... for November. Whether patients simply need routine care or have ... time than now to get that necessary care. The right ... off routine and even essential treatments due to financial concerns. ... savings on any treatments offered by the team at Christy ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Radiology ... see very little difference between diagnostic imaging centers ... of Marketing for DigitalOne. “Differentiation is critical ... in Radiology when you consider the intense competition ... Imaging of Salem will stand-out from the competition ...
Breaking Medicine News(10 mins):Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... the relationship between use of antidepressants and level ... the link between depression and level of alcohol ... Addiction and Mental Health (CAMH) concluded that women ... who did not experience depression, regardless of antidepressant ...
... conducted in eight hospitals in Peru concludes that opening ... lowers the risk of airborne contagion//. ,The ... than double that of mechanically ventilated negative-pressure rooms and ... closed. ,The researchers, led by Rod Escombe ...
... can effectively eliminate rabies in dogs//., ,The vaccine, ... developed by scientists at the High Security Animal Disease Laboratory ... capsule attracts stray dogs due to its artificial taste enhancers ... it. Once inside the dog's mouth, the capsule bursts and ...
... that single-slice magnetic resonance imaging (MRI) is a fast ... ,Excessive intra-abdominal fat is known to be a major ... illnesses in children and teenagers. , Unlike ... forming skin folds or "love handles," internal fat located ...
... should be brought into close physical contact with their ... Germany's Professional Association of Paediatricians (BVKJ) here. ... rate of development, grow faster and suffer less brain ... said spokesman Thomas Fendel. ,The hearts and ...
... An Indian American fitness guru has created a fusion of ... in the United States//. , ,Sarina Jain, also ... Bhangra' and is credited with the introduction of Bhangra, the ... ,Jain holds her aerobic classes all over the US, ...
Cached Medicine News:Health News:Antidepressants Help Men Decrease Alcohol Consumption, but Not Women 2Health News:Airborne Infection Less in Naturally Ventilated Rooms 2Health News:Single Slice MRI- Handy Tool to Identify Children at Risk 2
...
... The CoaguChek S System offers unparalleld ... just one minute requiring only 10 ... you to provide more comprehensive patient ... each patient. The CoaguChek S System ...
... The Instacup Multi-Drug Screen Panel is used for ... human urine. The Instacup Panel consists of a test ... the test card is inserted and the sample sealed ... It is not necessary to remove the test card ...
Detect LH surge for predicting ovulation, Able to detect as low as 40 mIU/mL LH or 30 mIU/mL LH, Simple, easy and accurate, Built-in control system...
Medicine Products: